Synthetic Artificial Blood Vessels Market

Rise in Cardiac Diseases and Peripheral Vascular Incidences to Boost Global Synthetic Artificial Blood Vessels Market

Increase in incidences of life-threatening peripheral vascular and cardiac cases, as well as an expanding pool of patients with unfulfilled treatment needs, are expected to boost the global synthetic artificial blood vessels market. In comparison to natural polymers, synthetic polymers possess infinite shapes, better tunable properties, and well-defined structures. The support provided by synthetic biomaterials can help to restore the function and structure of injured tissue.

Due to previous harvesting or the patient's condition, its is not always possible to carry on autologous replacement. In addition to that, autologous harvesting exposes the patient to subsequent damage at the site of harvest. Given the drawbacks of natural polymers, including scarcity, cost, cross contamination, and batch-to-batch fluctuation, synthetic polymers, such as biodegradable and non-biodegradable polymers, have progressed significantly as biomaterials in recent decades.

According to statistics, roughly 850,000 vascular repair operations are performed annually. Cardiovascular problems, which result in blocked or restricted blood arteries measuring less than 6 mm, are also the main reason for death worldwide. The need for vascular prosthesis is predicted to increase in the next few years to come due to these reasons. By correcting life-threatening conditions, these let the patient to enjoy a better life. Synthetic artificial blood arteries are good vascular grafts because they are flexible, minimize thrombogenicity, and infection risks. They are also capable of healing, contracting, and remodeling blood vessels. The global synthetic artificial blood vessels market is likely to benefit from all of these aspects.

Bioengineered Blood Vessels to Gain Traction in the Synthetic Artificial Blood Vessels Market

In the future years, the demand for bioengineered blood vessels is likely to skyrocket. For instance, if placed in the body of human beings, Humacyte's "bioengineered" blood arteries will utilize living cells. These human acellular vessels (HAVs) are being created to repopulate a patient's own cells and form a living vascular tissue for the best possible restorative result. In the forthcoming years, such breakthroughs in the medical area are expected to benefit the global synthetic artificial blood vessels market. In addition, the creation of absorbable biomaterials based on collagen is likely to expand the global synthetic artificial blood vessels market in a number of ways.

Rise in Research Activities to Drive Innovation in the Global Market

A rising market trajectory has been developed by intensified research efforts and an increase in demand for technically improved products. Healionics Corporation has secured $4.7 million in a round headed by Keiretsu Capital to assist commercialization of its STARgraft artificial blood vessel for dialysis patients. The Korea Institute of Science and Technology (KIST) stated that the Organ Transplantation Center at Seoul National University and Biomaterials Research Center collaborated on the development of a bio-artificial blood vessel. Scientists in Hong Kong and South Korea developed a biomimetic blood vessel that's been effectively implanted in a living rat using a modified 3D cell printing technology.

Synthetic biomaterials have a fundamental drawback in that they have shortage of cell attachment sites and must be chemically modified to improve cell adherence. Synthetic polymers also have a number of drawbacks in tissue engineering, including production of acidic breakdown products, poor biocompatibility, and loosing mechanical capabilities early during deterioration.

Better Reimbursement Policies and Diagnostic Systems to Drive North America Market

Due to its superior facilities, the North America synthetic blood vessel market is projected to lead the way. Moreover, better compensation policies and superior diagnostic methods have been recognized as key drivers in the regional market. Furthermore, rising research and development in the advanced biomaterial grafts field are expected to boost growth of the synthetic artificial blood vessel market in North America.

Europe has a significant share of the market and is expected to grow at a healthy pace in the forthcoming years. The rising incidence of cardiovascular disorders, as well as the aging populace, aortic disease, kidney failure, and various other health difficulties, is likely benefit regional players significantly.